Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Haemonetics (HAE) Stock Price

Media coverage about Haemonetics (NYSE:HAE) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 45.5612491222081 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

NYSE:HAE opened at $74.75 on Tuesday. The stock has a market capitalization of $3,918.77, a P/E ratio of 48.86, a price-to-earnings-growth ratio of 3.20 and a beta of 0.89. The company has a current ratio of 1.82, a quick ratio of 1.33 and a debt-to-equity ratio of 0.14. Haemonetics has a twelve month low of $38.47 and a twelve month high of $75.45.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.18. The business had revenue of $234.04 million for the quarter, compared to analyst estimates of $227.79 million. Haemonetics had a positive return on equity of 12.39% and a negative net margin of 1.94%. Haemonetics’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.43 earnings per share. equities analysts predict that Haemonetics will post 1.86 EPS for the current fiscal year.

Haemonetics announced that its board has authorized a stock repurchase plan on Tuesday, February 6th that allows the company to repurchase $260.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Several research firms have recently issued reports on HAE. Zacks Investment Research lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Jefferies Group reissued a “buy” rating and set a $80.00 target price on shares of Haemonetics in a report on Wednesday, February 7th. TheStreet lowered Haemonetics from a “b” rating to a “c+” rating in a report on Tuesday, February 6th. ValuEngine raised Haemonetics from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Finally, Barrington Research reissued an “outperform” rating and set a $71.00 target price (up from $57.00) on shares of Haemonetics in a report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Haemonetics has a consensus rating of “Hold” and an average target price of $71.33.

In related news, EVP Michelle L. Basil sold 389 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $72.23, for a total value of $28,097.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dan Goldstein sold 518 shares of the firm’s stock in a transaction dated Friday, April 6th. The shares were sold at an average price of $54.65, for a total value of $28,308.70. Following the completion of the sale, the vice president now directly owns 4,002 shares in the company, valued at $218,709.30. The disclosure for this sale can be found here. Insiders sold 1,329 shares of company stock worth $77,788 over the last ninety days. 1.20% of the stock is currently owned by insiders.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Haemonetics (HAE) Stock Price” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://weekherald.com/2018/04/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-haemonetics-hae-stock-price.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply